


IN THE CLAIMS


Please amend the claims as follows:

Claim 1 (Previously Presented): A method for selectively inhibiting the C-terminal site of angiotensin I converting enzyme comprising administering to a patient in need thereof at least one phosphinic pseudopeptide derivative comprising the amino acid sequence of formula (I) below:



wherein,


- R₂ and R₃, which are identical or different, represent the side chain of a natural or unnatural amino acid, the sequence:



also possibly forming the Pro (proline) residue, and


- R₅ represents a hydrogen atom, a pharmacologically acceptable counterion, or a group that forms an *in vivo* hydrolysable phosphinic ester.

Claim 2 (Previously Presented): A method for selectively inhibiting the C-terminal site of angiotensin I converting enzyme comprising administering to a patient in need thereof a phosphinic pseudopeptide derivative corresponding to formula (II) below:



wherein,

- R₁ represents a protecting group for an amine function, or an amino acid or a peptide protected with a protecting group for an amine function,
- R₂ and R₃, which may be identical or different, represent the side chain of a natural or unnatural amino acid, the sequence:



also possibly forming the Pro residue,


- R₄ represents a hydrogen atom or a pharmacologically acceptable counterion,
- and
- R₅ represents a hydrogen atom, a pharmacologically acceptable counterion, or a group that forms an *in vivo* hydrolysable phosphinic ester.

Claim 3 (Previously Presented): The method of Claim 2, wherein R₁ represents a protecting group for an amine function chosen from acetyl and benzyloxycarbonyl groups.

Claim 4 (Previously Presented): The method of Claim 1, wherein R₂ represents the benzyl, methyl or phenylethyl group.


Claim 5 (Previously Presented): The method of Claim 1, wherein R₃ represents the side chain of alanine, arginine or tryptophan.

Claim 6 (Previously Presented): The method of Claim 1, wherein the sequence $-\text{NH}-\text{CH}(\text{R}_3)-\text{CO}-$ forms the Pro residue:




Claim 7 (Currently Amended): The method of Claim 1, wherein R₄ and/or R₅ represent(s) a hydrogen atom.

Claim 8 (Previously Presented): The method of Claim 2, wherein the phosphinic pseudopeptide derivative is:




(pseudo-peptide G)

Claim 9 (Previously Presented): A phosphinic pseudopeptide derivative comprising the amino acid sequence of formula (I):




wherein,

- R₂ represents the side chain of a natural or unnatural amino acid,
- the sequence:



forms the Pro residue:




and

- R₅ represents a hydrogen atom, a pharmacologically acceptable counterion, or a group that forms an *in vivo* hydrolysable phosphinic ester.


Claim 10 (Previously Presented): A phosphinic pseudopeptide derivative of formula

(II):




wherein,

- R_1 represents a protecting group for an amine function, or an amino acid or a peptide protected with a protecting group for an amine function,
- R_2 represents the side chain of a natural or unnatural amino acid,
- the sequence:




forms the Pro residue:



- R_4 represents a hydrogen atom or a pharmacologically acceptable counterion,
- and
- R_5 represents a hydrogen atom, a pharmacologically acceptable counterion, or a group that forms an *in vivo* hydrolysable phosphinic ester.


Claim 11 (Previously Presented): A phosphinic pseudopeptide derivative of formula:




(pseudo-peptide G)

Claim 12 (Previously Presented): A pharmaceutical composition comprising at least one phosphinic pseudopeptide derivative as claimed in Claim 9.

Claim 13 (Previously Presented): A pharmaceutical composition, comprising a phosphinic pseudopeptide derivative of formula:




Claim 14 (Previously Presented): A process for preparing a pseudopeptide of formula:



wherein:

- R_1 represents a protecting group for an amine function, or an amino acid or a peptide protected with a protecting group for an amine function,
- R_2 and R_3 , which may be identical or different, represent the side chain of a natural or unnatural amino acid, the sequence:




also possibly forming the Pro residue, and


- R_4 and R_5 represent a hydrogen atom;

which comprises the following steps:


1) reacting a compound of formula (III):




in which R_1 and R_2 are as defined above, with the compound of formula (IV):




in which Ac represents the acetyl group and Et represents the ethyl group, to obtain the compound of formula (V):




2) converting compound (V) into compound (VI) by reacting compound (V) with sodium borohydride:




3) protecting the hydroxyl group of compound (VI) with a protecting group R_5 to give the compound of formula (VII):



4) saponifying compound (VII) to give the compound of formula (VIII):



5) coupling the compound of formula (VIII) with the amino acid of formula (IX) or (X):




in which R_3 is as defined above, and

6) removing the protecting group R_5 .


Claim 15 (Previously Presented): A process as claimed in Claim 14, wherein the peptide coupling step 5) is performed via solid-phase peptide synthesis wherein the solid phase is a resin substituted with the amino acid of formula (IX) or (X).

Claim 16 (Previously Presented): A process for preparing a pseudopeptide of formula:



wherein,

- R₁ represents a protecting group for an amine function, or an amino acid or a peptide protected with a protecting group for an amine function,
- R₂ and R₃, which may be identical or different, represent the side chain of a natural or unnatural amino acid, the sequence:




also possibly forming the Pro residue,

- R₄ represents a hydrogen atom, and
- R₅ represents a group that forms an *in vivo* hydrolysable phosphinic ester;

wherein the phosphinic function of the pseudopeptide obtained via the process of Claim 14 is esterified by coupling with an alcohol of formula R_5OH or by reaction with a halide of formula R_5X in which X represents a halogen atom.

Claim 17 (Previously Presented): A compound of formula (VIII):




wherein:

- Ad represents an adamantyl group,
- R_1 represents a protecting group for an amine function or an amino acid or a peptide protected with an amine function, and
- R_2 represents the side chain of a natural or unnatural amino acid.

Claim 18 (Previously Presented): The method of Claim 2, wherein R_2 represents the benzyl, methyl or phenylethyl group.

Claim 19 (Previously Presented): The method of Claim 2, wherein R_3 represents the side chain of alanine, arginine or tryptophan.

Claim 20 (Previously Presented): The method of Claim 2, wherein the sequence –
 $NH-CH(R_3)-CO-$ forms the Pro residue:




Claim 21 (Previously Presented): The method of Claim 2, wherein R_4 and/or R_5 represent(s) a hydrogen atom.

Claim 22 (Previously Presented): A pharmaceutical composition comprising at least one phosphinic pseudopeptide derivative as claimed in Claim 10.


Claim 23 (Previously Presented): A pharmaceutical composition comprising at least one phosphinic pseudopeptide derivative as claimed in Claim 11.

Claim 24 (Previously Presented): A process for preparing a pseudopeptide of formula:



wherein,

- R_1 represents a protecting group for an amine function, or an amino acid or a peptide protected with a protecting group for an amine function,
- R_2 and R_3 , which may be identical or different, represent the side chain of a natural or unnatural amino acid, the sequence:



also possibly forming the Pro residue,

- R₄ represents a hydrogen atom, and
- R₅ represents a group that forms an *in vivo* hydrolysable phosphinic ester;

wherein the phosphinic function of the pseudopeptide obtained via the process of Claim 15 is esterified by coupling with an alcohol of formula R₅OH or by reaction with a halide of formula R₅X in which X represents a halogen atom.

Claim 25 (Previously Presented): A process as claimed in Claim 14, wherein R⁵ is an adamantly group.